The National Center for Research of Epidemiology and Microbiology N. P. Gamalia, affiliated with the Ministry of Health, and the vaccine producer in partnership with the Russian Direct Investment Fund, said that the second phase of clinical trials of the vaccine showed efficacy of 91.4% on the 28th day after the first dose, and more than 95% after 42 days.
These positive results were obtained during the analysis of random group data that included about 40 thousand volunteers, which is the largest in the history of global trials to develop vaccines. The Russian researchers were able to produce the vaccine in a dry form by freezing at low temperatures, while it is stored at temperatures between + 2 and + 8 Celsius, which allows the vaccine to be distributed around the world in all hard-to-reach areas, including the tropical and hot tropical regions. Subscribe to «News» on YouTube Here
These were the details of the news The Russian Sputnik vaccine is cheaper and easier to store for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.